Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
Fennec Pharmaceuticals (NASDAQ: FENC) will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 at 1:00 p.m. ET. The session will be available via live webcast and an archived replay will be posted after the event.
Investors can access the live webcast via the provided webcast link or from the Events page in the Investors section of the company website (www.fennecpharma.com).
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FENC declined 0.75%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves, with CADL up 13.11% and IMMP up 5.2%, while VNDA and NMRA declined. With no momentum scanner hits or same-day peer news, today’s action appears company-specific.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Clinical trial update | Positive | +1.3% | Investigator-sponsored Phase I trial for PEDMARK in metastatic testicular tumors. |
| Dec 02 | Clinical topline data | Positive | -1.6% | Positive Phase 2/3 PEDMARK results in Japan reducing cisplatin-induced hearing loss. |
| Nov 26 | Conference participation | Neutral | -0.8% | Announcement of participation in Piper Sandler healthcare conference webcast session. |
| Nov 19 | Debt redemption | Positive | -6.5% | Company completed full redemption of Petrichor convertible notes, removing debt. |
| Nov 18 | Equity offering | Negative | +0.0% | Non-brokered Canadian share offering to institutional holders at US$7.50 per share. |
Positive clinical and balance sheet news often saw mixed or negative next-day moves, while neutral items like conference participation have drawn modest share price changes.
Over the last month, Fennec reported multiple financings and balance sheet actions, including equity offerings and full redemption of Petrichor convertible notes, leaving no outstanding debt as of Nov 19, 2025. It also delivered positive clinical updates for PEDMARK, including strong topline data from the Japanese STS-J01 study. A prior announcement about this same Piper Sandler conference on Nov 26, 2025 led to a modest -0.75% move, suggesting conference news has had limited price impact historically.
Market Pulse Summary
This announcement highlights Fennec’s plans to present at the Piper Sandler healthcare conference on December 3, 2025 via webcast, adding to its investor-relations outreach. Recent history shows more material developments around equity offerings, full debt redemption, and positive PEDMARK clinical data. Investors may monitor future updates on commercial progress, additional studies, and balance sheet changes, as those events have been more closely tied to past share price reactions than conference-related news.
AI-generated analysis. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 at 1:00 p.m. ET, which will be available via webcast.
| Webcast Detail: | |
| Date: | Wednesday, December 3, 2025 |
| Time: | 1:00 p.m. Eastern Time |
| Webcast Link: | https://event.webcasts.com/starthere.jsp?ei=1744934&tp_key=8b0c843aa1 |
The live webcast of the fireside chat will also be accessible on the Events page in the Investors section of the Company’s website (www.fennecpharma.com). An archived replay of the webcast will be available following the event.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI.
In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in the U.K. and Germany.
PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.
For more information, please visit www.fennecpharma.com and follow on LinkedIn.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
FAQ
When is Fennec Pharmaceuticals (FENC) presenting at the Piper Sandler conference?
How can I watch the Fennec (FENC) webcast for the December 3, 2025 fireside chat?
What is the direct webcast link for Fennec's December 3, 2025 presentation?
Will a replay of the Fennec (FENC) fireside chat be available after the event?
Where on the company website will the Fennec webcast be posted?
